维持性血液透析患者高磷血症应用碳酸司维拉姆治疗的临床分析

Clinical Analysis of the Application of Sevelamer Carbonate in the Treatment of Hyperphosphatism in Maintenance Hemodialysis Patients

目的:研究接受维持性血液透析治疗期间出现高磷血症患者采用碳酸司维拉姆对病情进行控制的临床价值。方法:选维持性血液透析期间出现高磷血症患者60例分成对照组和治疗组,每组30例。对照组采用醋酸钙进行治疗,治疗组采用碳酸司维拉姆进行治疗,比较治疗结果。结果:治疗组患者在用药前后血液检查相关指标的改善效果优于对照组(P<0.05);治疗组患者药物治疗总有效率(90.0%)高于对照组(63.3%),P<0.05;治疗组患者血液检查指标水平复常时间、用药总时间较对照组发生明显缩短(P<0.05);治疗组患者的不良反应发生率(3.3%)明显低于对照组(16.7%),有统计学意义(P<0.05)。结论:接受维持性血液透析期间出现高磷血症患者采用碳酸司维拉姆治疗可改善血压检查相关指标,减少不良反应,缩短用药时间,使效果提升。

Objective: To study the clinical value of Sevelamer carbonate in controlling the condition of patients with hyperphosphorus during maintenance hemodialysis. Methods: 60 patients with hyperphosphatemia during maintenance hemodialysis were selected and divided into a control group and a treatment group, with 30 patients in each group. The control group was treated with calcium acetate, the treatment group was treated with sevelamer carbonate, and the treatment results were compared. Results: Patients in the treatment group were better than those in the control group in the improvement of blood test-related indicators before and after treatment(P<0.05);the total effective rate of drug treatment(90.0%) was higher in the treatment group than in the control group(63.3%), P<0.05;The blood test index level of the treatment group was significantly shorter than that of the control group(P<0.05). The incidence of adverse reactions(3.3%) was significantly lower in the treatment group than in the control group(16.7%). Significance(P<0.05). Conclusion: Sevelamer carbonate treatment in patients with hyperphosphatemia during maintenance hemodialysis can improve blood pressure examination-related indicators, reduce adverse reactions, shorten medication time, and improve results.